Table 1.
AX origin | FA content (μg/mg AX) | Currently/potential application in biomedical/pharmaceutical field | Reference |
---|---|---|---|
Nejayote/maize bran | 0.012/0.025 | Entrapment of probiotic | [32] |
Nejayote/maize bran | 0.012/0.025 | Entrapment and controlled release of insulin and probiotics targeted to colon | [11] |
Maize bran | 0.34 | Controlled release of insulin and β-lactoglobulin | [33] |
Maize bran | 0.25 | Controlled release of insulin targeted to colon | [34] |
Maize bran | 4.0 | Entrapment and controlled release of methyl xanthine | [35] |
Wheat endosperm | 2.3 | Controlled release of proteins | [36] |
Wheat endosperm | 0.53 | Entrapment of probiotics | [37] |
Wheat bran | 0.435 | Antitumor and immunomodulatory activity | [16, 38] |
Wheat bran | — | Prebiotic | [39] |
Rice bran | — | Antitumor and immunomodulatory activity | [40] |
Rice bran (MGN-3/Biobran) | — | Cancer immunotherapy Prevention and inhibition of cancer Synergistic effect with chemotherapeutic agents |
[15, 41, 42] |
Finger millet bran | 0.001 | Immunomodulatory activity | [29] |
Ispaghula (Plantago ovata) seed | nd | Drug carrier | [31, 43] |
Ispaghula (Plantago ovata) seed | — | Controlled release of mucoadhesive oral films | [44, 45] |
nd: no detectable; −: no reported.